NeOnc Technologies Holdings, Inc. (NASDAQ:NTHI) ("NeOnc" or the "Company"), a clinical-stage biopharmaceutical company focused on advancing innovative therapies for central nervous system cancers, today announced that Chief Executive Officer, Executive Chairman, and President Amir Heshmatpour has significantly increased his personal ownership through consistent open-market purchases, including substantial buying in recent weeks, underscoring strong alignment with shareholders ahead of upcoming clinical and regulatory milestones.

Over the past year, Mr. Heshmatpour has invested nearly $1 million of personal capital into NeOnc shares. In recent weeks, he has purchased over $500,000 of additional stock in the open market, as reflected in Form 4 filings with the U.S. Securities and Exchange Commission, with further purchases anticipated.

NeOnc recently reported completion of NEO212's Phase 1 dose escalation and established a recommended Phase 2 dose, while its Phase 2a study of NEO100 in recurrent IDH1-mutant high-grade glioma remains fully enrolled with an interim analysis expected later this year.